Intersect ENT, Inc., a drug delivery company, researches and develops products for the treatment of patients with ear, nose and throat conditions in the United States. It offers PROPEL and PROPEL mini drug releasing implants for patients undergoing sinus surgery to treat chronic sinusitis; and PROPEL Contour, a steroid releasing implant to frontal and maxillary sinus ostia, or openings, of the dependent sinuses. The company is also developing SINUVA, a steroid releasing implant for refractory disease for the treatment of patients in the physician office setting. The company was formerly known as Sinexus, Inc. and changed its name to Intersect ENT, Inc. in November 2009. Intersect ENT, Inc. was founded in 2003 and is headquartered in Menlo Park, California.
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:XENT
CUSIPN/A
Phone650-641-2100
Debt
Debt-to-Equity RatioN/A
Current Ratio8.99
Quick Ratio8.39
Price-To-Earnings
Trailing P/E Ratio-65.80
Forward P/E Ratio-57.58
P/E GrowthN/A
Sales & Book Value
Annual Sales$96.30 million
Price / Sales11.53
Cash FlowN/A
Price / CashN/A
Book Value$3.98 per share
Price / Book9.26
Profitability
EPS (Most Recent Fiscal Year)($0.56)
Net Income$-16,360,000.00
Net Margins-15.73%
Return on Equity-13.67%
Return on Assets-12.06%
Miscellaneous
Employees327
Outstanding Shares30,140,000
Intersect ENT (NASDAQ:XENT) Frequently Asked Questions
What is Intersect ENT's stock symbol?
Intersect ENT trades on the NASDAQ under the ticker symbol "XENT."
How were Intersect ENT's earnings last quarter?
Intersect ENT Inc (NASDAQ:XENT) issued its quarterly earnings data on Tuesday, May, 1st. The medical equipment provider reported ($0.21) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.23) by $0.02. The medical equipment provider earned $24.70 million during the quarter, compared to the consensus estimate of $23.66 million. Intersect ENT had a negative return on equity of 13.67% and a negative net margin of 15.73%. The firm's revenue was up 20.5% compared to the same quarter last year. During the same period last year, the company earned ($0.23) earnings per share. View Intersect ENT's Earnings History.
When is Intersect ENT's next earnings date?
What price target have analysts set for XENT?
9 brokers have issued twelve-month target prices for Intersect ENT's shares. Their forecasts range from $31.00 to $48.00. On average, they anticipate Intersect ENT's share price to reach $37.5714 in the next year. View Analyst Ratings for Intersect ENT.
What are Wall Street analysts saying about Intersect ENT stock?
Here are some recent quotes from research analysts about Intersect ENT stock:
- 1. Canaccord Genuity analysts commented, "We reiterate our BUY rating on XENT and view ongoing share weakness as a buying opportunity. Specifically, shares are down ~9% intraday following the release of preliminary CMS guidelines that deny XENT’s request for a standalone J-code for Sinuva. The decision was disclosed in the CMS preliminary agenda for the upcoming Public Meeting for Drugs, Biological, and Radiopharmaceuticals held on May 15, 2018 (link). In the preliminary guideline CMS denies XENT’s request for a product-specific J-code and instead assigns Sinuva to an old and soon to be defunct (as of Jan 1, 2019) Category 3 CPT code – 0406T. Our conversation with management suggests the decision in the preliminary guidelines was likely an oversight on the part of CMS and something that will likely be addressed when the topic presented at the meeting on May 15." (5/7/2018)
- 2. According to Zacks Investment Research, "Intersect ENT, Inc. is a commercial drug-device company. The Company's initial products, PROPEL and PROPEL mini, are drug-eluting implants for use in patients with chronic sinusitis. It offers products and therapies for ear, nose, and throat surgeons to improve treatment for their patients with chronic diseases. Intersect ENT, Inc. is headquartered in Menlo Park, California. " (5/5/2018)
- 3. Northland Securities analysts commented, "We are raising our FY18 and FY19 numbers, in part due to elevated expectations on SINUVA. In our view, this story of marginal beats and managing Street expectations" is not enough to elevate the stock from its current 10x sales multiple." (5/2/2018)
Who are some of Intersect ENT's key competitors?
Some companies that are related to Intersect ENT include Cantel Medical (CMD), NuVasive (NUVA), Novocure (NVCR), Merit Medical Systems (MMSI), Nevro (NVRO), Irhythm Technologies (IRTC), Mazor Robotics (MZOR), Glaukos (GKOS), Luminex (LMNX), Orthofix International (OFIX), Atrion (ATRI), Cardiovascular Systems (CSII), OraSure Technologies (OSUR), Tandem Diabetes Care (TNDM) and Cryolife (CRY).
Who are Intersect ENT's key executives?
Intersect ENT's management team includes the folowing people:
- Ms. Lisa D. Earnhardt, Chief Exec. Officer, Pres and Director (Age 48)
- Ms. Jeryl L. Hilleman M.B.A, Chief Financial Officer (Age 60)
- Mr. Richard E. Kaufman, Chief Operating Officer (Age 56)
- Mr. David A. Lehman, Gen. Counsel & Sec. (Age 57)
- Ms. Gwen R. Carscadden, Chief People Officer (Age 57)
Has Intersect ENT been receiving favorable news coverage?
News headlines about XENT stock have trended somewhat positive recently, according to Accern Sentiment. The research firm identifies negative and positive press coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Intersect ENT earned a media sentiment score of 0.15 on Accern's scale. They also gave press coverage about the medical equipment provider an impact score of 46.24 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company's share price in the next several days.
Who are Intersect ENT's major shareholders?
Intersect ENT's stock is owned by a number of of institutional and retail investors. Top institutional investors include BlackRock Inc. (6.43%), Federated Investors Inc. PA (2.93%), Neuberger Berman Group LLC (1.77%), Rock Springs Capital Management LP (1.36%), Lord Abbett & CO. LLC (1.28%) and Northern Trust Corp (1.18%). Company insiders that own Intersect ENT stock include Amy Wolbeck, David Aaron Lehman, Frederic H Moll, Gwen R Carscadden, James Stambaugh, Jeryl L Hilleman, Lisa D Earnhardt and Richard E Kaufman. View Institutional Ownership Trends for Intersect ENT.
Which major investors are selling Intersect ENT stock?
XENT stock was sold by a variety of institutional investors in the last quarter, including Federated Investors Inc. PA, Neuberger Berman Group LLC, Citigroup Inc., Millennium Management LLC, BlackRock Inc., GSA Capital Partners LLP, Tiverton Asset Management LLC and A.R.T. Advisors LLC. Company insiders that have sold Intersect ENT company stock in the last year include David Aaron Lehman, Frederic H Moll, Gwen R Carscadden, Jeryl L Hilleman, Lisa D Earnhardt and Richard E Kaufman. View Insider Buying and Selling for Intersect ENT.
Which major investors are buying Intersect ENT stock?
XENT stock was bought by a variety of institutional investors in the last quarter, including Matarin Capital Management LLC, Public Employees Retirement Association of Colorado, Loomis Sayles & Co. L P, Royal Bank of Canada, Bamco Inc. NY, Rock Springs Capital Management LP, Sivik Global Healthcare LLC and Thrivent Financial for Lutherans. View Insider Buying and Selling for Intersect ENT.
How do I buy shares of Intersect ENT?
Shares of XENT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Intersect ENT's stock price today?
One share of XENT stock can currently be purchased for approximately $36.85.
How big of a company is Intersect ENT?
Intersect ENT has a market capitalization of $1.10 billion and generates $96.30 million in revenue each year. The medical equipment provider earns $-16,360,000.00 in net income (profit) each year or ($0.56) on an earnings per share basis. Intersect ENT employs 327 workers across the globe.
How can I contact Intersect ENT?
Intersect ENT's mailing address is 1555 ADAMS DRIVE, MENLO PARK CA, 94025. The medical equipment provider can be reached via phone at 650-641-2100 or via email at [email protected]
MarketBeat Community Rating for Intersect ENT (XENT)
MarketBeat's community ratings are surveys of what our community members think about Intersect ENT and other stocks. Vote "Outperform" if you believe XENT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe XENT will underperform the S&P 500 over the long term. You may vote once every thirty days.
